Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

Rosenbaum, C. E. N. M.; van den Hoven, A. F.; Braat, M. N. G. J. A.; Koopman, M.; Lam, M. G. E. H.; Zonnenberg, B. A.; Verkooijen, H. M.; van den Bosch, M. A. A. J.

doi:10.1186/s13550-016-0236-1

EJNMMI Research

Table 5 Overview of previous studies on angiogenic factors and transarterial treatment of liver tumours

From: Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response

Author	Year	Patients	Treatment	Factors	Samples collected	Results
Carpizo et al. [28]	2014	n = 15 CRCLM	⁹⁰Y-RE	VEGF, Ang-2, b-FGF, PDGF-BB, TSP-1, follistatin, leptin, IL-8	Baseline	* Transient increases in many angiogenic cytokines * Some changes associated with worse OS
Carpizo et al. [28]	2014	n = 7 HCC	⁹⁰Y-RE		6 h, and 3, 14, 30, 60, 90 and 120 days of follow-up
Korse et al. [27]	2011	n = 12 NET	HAE	VEGF, ET-1, proET-1	Baseline	* VEGF and proET-1 showed temporarily increase after treatment
Korse et al. [27]	2011	n = 12 NET	HAE	VEGF, ET-1, proET-1	1, 2, 3, 4, 5, 6, 7 and 8 days of follow-up
Sergio et al. [10]	2008	n = 71 HCC	TACE	VEGF, b-FGF, uPA	Baseline	* VEGF levels were higher in non-responders at 1-month follow-up
Sergio et al. [10]	2008	n = 71 HCC	TACE	VEGF, b-FGF, uPA	3 and 30 days of follow-up	* Below-median VEGF levels predicted a longer survival
Shim et al. [26]	2008	n = 147 HCC	TACE	VEGF	Baseline	* High increment in serum VEGF level 1–2 days post treatment was associated with distant metastasis and unfavourable outcomes
Shim et al. [26]	2008	n = 147 HCC	TACE	VEGF	1–2 and 30 days of follow-up
Li et al. [8]	2004	n = 45 HCC	TACE	VEGF	Baseline	* A high pre-treatment VEGF level was associated with poor response
		n = 20 benign disease			1, 3, 7 and 30 days of follow-up
		n = 17 healthy controls			1, 3, 7 and 30 days of follow-up	* VEGF levels increased significantly on the first day post treatment
Suzuki et al. [9]	1999	n = 38 HCC	TAE	VEGF, HGF	Baseline	* No significant alterations in HGF levels
Suzuki et al. [9]	1999	n = 38 HCC	TAE	VEGF, HGF	1, 3 and 7 days of follow-up	* VEGF levels increased significantly at 7 days post treatment

CRCLM colorectal cancer liver metastases, HCC hepatocellular carcinoma, ⁹⁰ Y-RE yttrium-90 radioembolization, VEGF vascular endothelial growth factor, Ang-2 angiopoietin-2, b-FGF basic fibroblast growth factor, PDGF-BB platelet-derived growth factor subunit BB, TSP-1 thrombospondin-1, IL-8 interleukin-8, NET neuroendocrine tumours, HAE hepatic artery embolization, ET-1 endothelin-1, proET-1 proendothelin-1, TACE transarterial chemoembolization, uPA urokinase-type plasminogen activator, TAE transarterial embolization, HGF hepatocyte growth factor

Back to article page